EUCTR2005-002854-22-IT进行中（未招募）不适用
A 24-month, multicenter, randomized, open label non inferiority study of efficay and safety comparing concentration- controlled Certican in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral versus 1.44 Myfortic with standard dose Neoral in de-novo renal transplant recipients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 825
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria ? Male or female renal recipients 18-70 years of age undergoing primary kidney transplantation, females not pregnant or lactating ? Recipients of primary cadaveric, living unrelated or non HLA identical living related donor ? Patients who have given written informed consent to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria ? Cold ischemia time >40 hours, non-heartbeating donor , donor age >65 ? Patients with platelet count <100,000/mm at the evaluation before randomization. ? Patients with an absolute neutrophil count of < 1,500/mm³ at baseline before surgery or white blood cell count of < 4,500/mm³ ? Patients who are recipients of multiple solid organ transplants, or who previously received an organ transplant ? Patients who have severe hypercholesterolemia (>350 mg/dL; >9 mmol/L) or hypertriglyceridemia (>500 mg/dL; >8.5 mmol/L). Patients with controlled hyperlipidemia are acceptable ? Patients who have an abnormal liver profile such as ALT, AST, Alk Phos or total bilirubin >3 times the ULN ? Patients who are treated with drugs that are strong inducers or inhibitors of cytochrome P450, patients treated with terfenadine, astemizole, cisapride or lovastatin ? Patients who received an investigational drug or who have been treated with a non-protocol immunosuppressive drug or treatment within 30 days or 5 half-lives prior to randomization ? Patients with a history of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin
研究者
相似试验
进行中（未招募）
不适用
A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0g MMF with standard dose Neoral in de novo heart transplant recipients. -de novo heart transplantationEUCTR2005-003413-32-GBovartis Pharma Services AG590
进行中（未招募）
1 期
A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled Certican® in two doses (1,5 and 3,0 mg/day starting doses) with reduced Neoral® versus 1,44 g Myfortic® with standard dose Neoral in de novo renal transplant recipientsrenal transplantationMedDRA version: M15Classification code 10038533EUCTR2005-002854-22-SKovartis Pharma Services AG
进行中（未招募）
不适用
A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled Certican® in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral? versus 1.44 g Myfortic? with standard dose Neoral in de novo renal transplant recipientsEUCTR2005-002854-22-SEovartis Pharma Services AG825
进行中（未招募）
1 期
A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled Certican® in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral® versus 1.44 g Myfortic ® with standard dose Neoral® in de novo renal transplant recipients -renal transplantationEUCTR2005-002854-22-GBovartis Pharma Services AG
进行中（未招募）
1 期
A 24-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0 g MMF with standard dose Neoral in de novo heart transplant recipientsde novo heart transplantationEUCTR2005-003413-32-DKovartis Pharma Services AG630